Alector, Inc. $ALEC Shares Purchased by 683 Capital Management LLC

683 Capital Management LLC raised its holdings in Alector, Inc. (NASDAQ:ALEC) by 235.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,350,000 shares of the company’s stock after buying an additional 2,350,000 shares during the period. 683 Capital Management LLC’s holdings in Alector were worth $5,226,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Savant Capital LLC acquired a new position in shares of Alector in the 3rd quarter valued at approximately $35,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Alector in the 4th quarter valued at approximately $30,000. Hershey Trust Co. raised its position in shares of Alector by 100.0% in the 4th quarter. Hershey Trust Co. now owns 20,572 shares of the company’s stock valued at $32,000 after purchasing an additional 10,286 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Alector in the 2nd quarter valued at approximately $30,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Alector in the 4th quarter valued at approximately $40,000. 85.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alector

In other news, CFO Neil Lindsay Berkley sold 19,360 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total value of $38,139.20. Following the completion of the transaction, the chief financial officer owned 379,900 shares of the company’s stock, valued at approximately $748,403. This represents a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Arnon Rosenthal sold 87,216 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total value of $171,815.52. Following the completion of the transaction, the chief executive officer directly owned 2,367,206 shares of the company’s stock, valued at approximately $4,663,395.82. The trade was a 3.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 117,580 shares of company stock valued at $232,557. Company insiders own 8.30% of the company’s stock.

Analyst Upgrades and Downgrades

ALEC has been the subject of a number of research analyst reports. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alector in a report on Monday, May 4th. Morgan Stanley reiterated an “underweight” rating and issued a $2.00 price target on shares of Alector in a report on Monday, May 4th. BTIG Research upgraded Alector from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Tuesday, March 10th. Finally, Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a report on Wednesday, April 15th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alector currently has a consensus rating of “Hold” and an average price target of $3.63.

Alector Price Performance

Shares of ALEC opened at $1.56 on Thursday. The company has a market cap of $173.21 million, a P/E ratio of -1.31 and a beta of 0.61. The stock has a fifty day moving average price of $2.16 and a 200 day moving average price of $1.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.25 and a quick ratio of 5.25. Alector, Inc. has a 12 month low of $1.09 and a 12 month high of $3.40.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $9.67 million. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%. On average, research analysts forecast that Alector, Inc. will post -0.86 earnings per share for the current year.

Alector Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.